Key Summary Points {#FPar1}
==================

**Why carry out this study?** Exposure to waste anaesthetic gases (WAGS) that leak into operating rooms during anaesthetic delivery can lead to short-term and long-term adverse effects. Although precautionary practices are often implemented to minimise anaesthetic gas leakage, leakage can still occur (e.g. during filling of vaporizers). The aim of this study was to test the hypothesis that use of a closed valve vaporizer filling system would maintain the presence of sevoflurane within or below recommended exposure limits.**What was learned from this study?** Sevoflurane exposures in the breathing zone were well below the recommended guidance from both National Institute for Occupational Safety and Health (NIOSH) and the Swedish Work Environment Authority for exposure limits when the vaporizer is filled using a closed filling system. Use of the closed vaporizer filling system evaluated here can help to minimise occupational exposure to WAGs in an operating room environment.

Introduction {#Sec1}
============

The US National Institute for Occupational Safety and Health (NIOSH) defines waste anaesthetic gases (WAGs) as small amounts of volatile anaesthetic gases leaking into operating rooms during anaesthetic delivery \[[@CR1], [@CR2]\]. In the USA, chronic exposure to WAGs affects more than 200,000 healthcare professionals, including anaesthesiologists, surgeons, operating room nurses and technicians \[[@CR1], [@CR3], [@CR4]\]. Short-term exposure (acute; during or within hours after anaesthesia procedure) to high concentrations of WAGs could lead to headache, irritability, nausea and drowsiness immediately upon or shortly after exposure, whereas long-term exposure (chronic; working over months or years in an operating room setting) to low concentrations is associated with genetic anomalies, miscarriage, birth defects and malignancy that may occur after several months \[[@CR1], [@CR5]--[@CR8]\].

Waste gases include nitrous oxide and halogenated anaesthetics \[[@CR1]\]. Halogenated compounds are among the most common anaesthetics in clinical practice \[[@CR9]\]. Halogenated inhaled anaesthetics are volatile liquids that are transferred from a closed bottle to a vaporizer using a valving system, which allows the anaesthetic agent to be poured into the vaporizer \[[@CR10]\]. Although precautionary practices are often set to minimise excess anaesthetic gas leakage \[[@CR2], [@CR5]\], contamination of operating rooms can still occur through different pathways, including improper anaesthetic handling techniques that cause spillage of anaesthetics during the filling of vaporizers \[[@CR11]\].

The effects of anaesthetic gas exposure are dependent on the concentration of the agent and the duration of exposure. Sevoflurane is one of the most widely used inhaled anaesthetic agents \[[@CR9], [@CR12], [@CR13]\]. Although no US federal regulatory standard exists for sevoflurane exposure limits \[[@CR9]\], NIOSH guidelines advise that occupational exposure limits to halogenated gases should not exceed a 60-min ceiling of 2 ppm over the period of anaesthetic administration \[[@CR2], [@CR12]\]. The US National Institutes of Health also recommends an occupational exposure limit of sevoflurane to 2 ppm as a time-weighted average (TWA) representing the average exposure over a schedule of 8 h per day or 40 h per week \[[@CR14]\]. In Europe, the Swedish Work Environment Authority recommends a short-term value of 20 ppm average over 15 min \[[@CR15]\].

Use of a closed valving system to fill anaesthetic vaporizers with sevoflurane has been shown by Heijbel et al. to result in 63% lower levels of waste gas exposure compared with concentrations observed during use of a different filling system (*P* = 0.016) \[[@CR16]\]. However, the study by Heijbel et al. did not measure sevoflurane concentrations at different heights. Ready-to-use sevoflurane bottles incorporating AbbVie's closed valving system (Quik-Fil™; AbbVie Inc., North Chicago, IL, USA) are now available. The objective of this study was to establish the validation of the previous study by Heijbel et al. \[[@CR16]\] to further demonstrate that, while using this closed valving system, the presence of sevoflurane in the breathing zone as normally located in an operating room would be within or below recommended exposure limits at different heights.

Methods {#Sec2}
=======

This was a prospective, open, exploratory study conducted in a laboratory setting at room temperature (approximately 20--21 °C). The laboratory where the experiment was conducted had an air handling system that displaced approximately 6--12 volume changes per hour, to approximate the air exchange rate of an operating room. The study was sponsored by AbbVie Inc. (North Chicago, IL, USA), and the working procedure was reviewed and approved by AbbVie Global Medical Affairs.

Filling Technique {#Sec3}
-----------------

The experimental setup and filling procedure are depicted in Fig. [1](#Fig1){ref-type="fig"}. Nine separate filling runs were performed in this study. In each run, five Dräger Vapor^®^ 2000 vaporizers (Dräger Medical AG & Co. KGaA, Lübeck, Germany) were sequentially filled with sevoflurane (Ultane^®^, AbbVie Inc., North Chicago, IL, USA) from anaesthetic bottles kept at room temperature and using the integrated closed valving system. Within each run, the first vaporizer was filled, which took approximately 3 min, then that vaporizer was closed and filling of the next vaporizer began; this continued until the fifth vaporizer was full, so that the total time of each run was approximately 15 min. Each vaporizer was filled from a new bottle. The number of vaporizers per run and the total time per run were based on usual practice for this type of study. The five vaporizers for each run were taken from a pool of 25 calibrated vaporizers; because a total of 45 vaporizer fillings (nine runs × five fillings per run) were completed in the study, some vaporizers were reused, after complete drying.Fig. 1Filling procedure and experimental setup. **a** To fill the individual vaporizers using the closed valving system, operators inserted a bottle of sevoflurane directly into the vaporizer; filling was accomplished by gravity-based flow. **b** The equipment setup included a vaporizer mounted to a fixed-height interface and an ambient air analyser placed at different heights. Five vaporizers were filled per run, and nine total runs were performed; the height of the air analyser varied across runs. **c** Vaporizer filling was performed in a standing or sitting position to accommodate operator height, with the air analyser (black square) placed at various heights in the breathing zone

The filling procedure was performed by two operators, who were laboratory personnel; operator A was 168 cm tall and had very little experience filling anaesthetic vaporizers, and operator B was 186 cm tall and had 10 years of experience filling anaesthetic vaporizers.

Measurement of Sevoflurane Concentrations {#Sec4}
-----------------------------------------

The maximum and minimum ambient-air sevoflurane concentrations in the breathing zone (midway between the vaporizer and approximately 15 cm from the nose or mouth) during the 15-min fill time were measured in units of ppm every second (total of approximately 900 measurements per vaporizer per 15-min run period) using a MIRAN SapphIRe 205BXL (Thermo Fisher Scientific, Franklin, MA, USA). This device is part of a family of air analysers that utilise infrared detection to monitor the presence of gases in ambient air. By selecting a measurement wavelength for the target gas that is not common to any other gas, the problem of interference by other components of the air can be avoided. A microcontroller automatically handles the analysis, processes the measurement signal, and calculates the absorbance values.

To assess sevoflurane exposure at different typical operator positions (i.e. sitting and standing, with the breathing zone close to and far from the vaporizer, respectively), ambient sevoflurane air concentrations were measured with the air analyser at different heights relative to the floor in each of the nine runs: 95, 130, 140, 150, 160, and 185 cm. The vaporizers remained at a fixed height from the floor (125 cm to the fill valve and 130 cm to the mounting point). Observed sevoflurane concentrations were compared against the recommended short-term value of 20 ppm average for 15 min provided by the Swedish Work Environment Authority and the US limit of a TWA of 2 ppm during 1 h or less provided by the NIOSH \[[@CR2], [@CR15]\].

Compliance with Ethics Guidelines {#Sec5}
---------------------------------

This work represents a laboratory study; no ethical committee approval was required and no human subjects were involved.

Results {#Sec6}
=======

Under the circumstances of this study, the use of the closed vaporizer filling system maintained maximum, minimum, and mean levels (means were calculated automatically by the MIRAN SapphIRe 205BXL instrument) of sevoflurane WAG exposure well below the recommended guidelines provided by the Swedish Work Environment Authority and NIOSH. Across all 45 readings (nine runs, each with five vaporizers filled sequentially) considered together, the mean concentration was 0.10 ppm. Among any of the nine runs considered independently, the mean sevoflurane concentration ranged from 0 to 0.09 ppm, the maximum sevoflurane concentration ranged from 0 to 0.16 ppm, and the minimum sevoflurane concentration ranged from 0 to 0.01 ppm. No trends in sevoflurane concentrations were apparent whether the results were considered according to the height of the operator breathing zone (Fig. [2](#Fig2){ref-type="fig"}) or by the order in which the nine runs were conducted over 3 days (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Ambient sevoflurane concentrations measured at different heights. Columns represent mean sevoflurane concentrations; error bars represent maximum/minimum values. Repeat measurements are from two different operators, indicated by superscript numbers (^1^ and ^2^). Asterisks indicate minimum detection level not reachedFig. 3Sevoflurane exposure by sequential run number during each 15-min filling with closed valving system. Columns represent mean sevoflurane concentrations; error bars represent maximum and minimum values. Asterisks indicate minimum detection level not reached

Discussion {#Sec7}
==========

Leakage of WAG can result from many causes, including but not limited to the filling of anaesthetic vaporizers \[[@CR11]\]. The results of this study support the use of the closed anaesthetic filling system, which can be an effective tool as part of an efficient WAG management system. The mean value of 0.10 ppm over 45 readings confirms the supposition that the use of the closed vaporizer filling system maintains a level of WAG exposure well below the recommended short-term value of 20 ppm provided by the Swedish Work Environment Authority \[[@CR15]\]. The results also fall below the US limit of a TWA of 2 ppm provided by NIOSH and the Occupational Safety and Health Administration \[[@CR2], [@CR3]\].

Our study results for the ambient concentration of sevoflurane using filling from an integrated closed valving system were lower than those previously reported by Heijbel et al. \[[@CR16]\] and demonstrated consistency regardless of operator height and despite different levels of skill when filling the sevoflurane vaporizer using the closed filling system. In operating rooms, scavenging systems (e.g. passive single-pass or recirculating systems that vent gases to exhaust/disposal sites, passive adsorbers such as canisters of activated charcoal, and active negative-pressure-based systems that remove gases via a central vacuum or dedicated exhaust) are used to help reduce exposure to gases as well as for antiseptic purposes \[[@CR14]\]. However, residual sevoflurane concentrations can still exceed the limits recommended by NIOSH \[[@CR17]\]. Given that most anaesthesia care providers outside the USA (anaesthesiologists, nurse anaesthetists and assistants) use a closed filling system \[[@CR5]\] and considering that the closed vaporizer filling technology results in nearly 60% less exposure of sevoflurane contamination of ambient air than another filling system \[[@CR16]\], our own finding of minimal exposure in breathing zone air validates the usefulness of the closed vaporizer filling technology.

Several limitations of our findings should be noted. This study was not a comparative evaluation but rather a validation of one vaporizer filling system and, therefore, should be evaluated on its own stand-alone merits. An environmental difference in our experiments was the absence of background sevoflurane "scatter", which would be expected in a working operating room environment. Further studies need to be conducted since the data obtained from this study could be affected by the environment, equipment and personnel present in an operating room setting.

Conclusions {#Sec8}
===========

The use of the closed filling system maintained sevoflurane exposures well below the recommended NIOSH and Swedish guidance in the breathing zone, irrespective of operator height. The use of this closed filling system can help to minimise occupational exposure to halogenated anaesthetic hazards in an operating room environment.
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